BioCentury
ARTICLE | Company News

Affitech cancer news

July 23, 2012 7:00 AM UTC

Affitech shareholder Trans Nova Investments Ltd. made a new offer to acquire the 28.7% of Affitech it does not already own for DKK0.20 per share in cash. Earlier this month, Affitech said NASDAQ OMX Copenhagen would accept the company's request to delist contingent on a new offer from Trans Nova. The offer expires on Aug. 28. Trans Nova also provided a €1.5 million ($1.8 million) loan to Affitech. The loan bears interest at three-month EURIBOR plus 2% and matures on Oct. 16. Affitech received the first €500,000 ($611,350) tranche this month and expects to receive two equal tranches in August and September. Details were not disclosed (see BioCentury, July 16). ...